ITOC-2 – 2015

ITOC2_Banner_695x90 new

The second edition of ITOC took place at the Klinikum rechts der Isar in Munich, Germany, from 25 to 27 March 2015. The meeting is growing rapidly into a global platform for translational research in the field of immuno-oncology. Organized by the Cancer Drug Development Forum, the ITOC conference series aims to provide a forum for discussion of early clinical drug development and address its unique challenges.

For this second edition, the conference again has surpassed our expectations in terms of attendance and participants. Our excellent scientific programme with an international faculty focused on many topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T-cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.


20150327_090507ITOC-2 presented plenary sessions on “Immune Suppression and Microenvironment”, “Checkpoint Inhibition”, “Combination Therapy”, “Immunomodulatory Agents”, Anti-cancer Vaccines”, “Monitoring of Immunotherapy”, “Adoptive T-Cell Therapy”, and “Engineered T-Cell Therapy”.

A keynote lecture was given by Prof. Alexander M.M. Eggermont, Institut Gustave Roussy (France) on Combining Immunomodulatory and/or Targeted Agents.


The scientific programme of ITOC-2 was completed with:

Four sponsored satellite symposia:

  • “Cancer Immunotherapy: translating innovative science into clinical trials” – F.Hoffmann-La Roche
  • “Broadening the horizon of Immuno-Oncology in 2015: Melanoma, lung cancer and beyond” – Bristol-Myers Squibb
  • “Checkpoint Inhibition: Transforming Breakthrough Science into Better Patient Care” – Merck MSD
  • “CARs and Cell Therapy: Today and the Road Ahead – Novartis
20150327_091106Eight Poster Sessions which tackled topics such as “Microenvironment and Inflammation”, “Immunosuppression”, Therapeutic Modulation of Immune Checkpoints”, Anti-cancer Vaccines”, “Antibody Therapy”, “Engineerd T-cell Therapy”, “combination Therapy”, “Monitoring of Immunotherapy”.


The poster awards were sponsored by the Munich Tumor Center and given to:

  • Winner – Mrs Sc. L. POSSELT, Klinikum der Universität München, Munich, Germany. Poster: “Therapy of Hepatocellular Carcinoma (HCC) with Immunostimulatory RNA Activating RIG-I.”
  • Runner-up – Mrs C-I. URECHE, Hannover Medical School, Germany. Poster: “Redirecting Adenovirus-Specific T Cells by a Tumour-Specific T Cell Receptor for Therapy of Hepatocellular Carcinoma.”
  • Third Place – Ms S. KARAKHANOVA, University of Heidelberg, Germany. Poster: “Immunosuppressive Microenvironment in Pancreatic Adenocarcinoma.”


European Journal of Cancer (EJC)
Volume 51, Supplement 1, Pages S1-S14, March 2015

  • Read the ITOC-2 Abstract Book online here.


  • Read and download the PDF version of the Final Scientific Programme of ITOC-2 here.


The ‘Cancer Drug Development Forum (CDDF)’ (or) ‘2nd Immunotherapy of Cancer Conference’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS),

The ‘2nd Immunotherapy of Cancer Conference’ is designated for a maximum of (or ‘for up to’) 13 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.